research use only

RGFP966 HDAC3 inhibitor

Name: RGFP966
Brand: Selleck Chemicals
SKU: S7229
Availability: InStock
Rating: 5 (118 reviews)

Cat.No.S7229

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.

Chemical Structure

Molecular Weight: 362.4

Jump to Mechanism of Action Cell Culture & Working Concentration Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.74%

99.74

Products Often Used Together with RGFP966

Tubastatin A

It and Tubastatin A decrease total HDAC activity in HLMVEC and reduce the inflammatory and hyper-permeability response to LPS in mice.

(+)-JQ1

It and JQ1 dramatically reduces tumor volume and growth rate and suppresses tumor growth via induction of apoptosis in the glioma xenograft mouse model.

TSA (Trichostatin A)

It and Trichostatin A increase the expression of AKAP12 at both the mRNA and protein levels.

Related Targets	Epigenetic Reader Domain JAK Histone Methyltransferase AMPK PKC PARP HIF Histone Acetyltransferase Aurora Kinase Sirtuin PRMT Histone Demethylase EZH1/2 DNA Methyltransferase Pim LSD1 MLL JMJD G9a/GLP NSD FTO MicroRNA PAD SETD SMYD DOT1 COMT WDR5 HNMT SAM MTase
Related Products	Entinostat (MS-275) TSA (Trichostatin A) Mocetinostat (MGCD0103) Tubastatin A Ricolinostat (ACY-1215) Quisinostat (JNJ-26481585) Dihydrochloride MC1568 Tubastatin A HCl PCI-34051 Tacedinaline (CI994) LMK-235 Fimepinostat (CUDC-907) Tubacin Givinostat (ITF-2357) Hydrochloride Monohydrate TMP269 AR-42 Sodium butyrate Pracinostat (SB939) Santacruzamate A (CAY10683) Abexinostat (PCI-24781) (-)-Parthenolide CUDC-101 Dacinostat (LAQ824) CAY10603 RG2833 (RGFP109) Tasquinimod Tucidinostat (Chidamide) TMP195 Nexturastat A Droxinostat

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
APL cells	Function assay	≤2 μM	48 h	DMSO	RGFP966 did not induce apoptosis in APL cells but did reduce clonogenicity and increased maturation.	26447190
Em-Myc lymphoma cells	Function assay	≤1 μM	48 h	DMSO	Cell proliferated significantly more slowly than vehicle-treated controls in the presence or absence of pro-survival BCL-2 overexpression	26447190
HH and Hut78 cells	Proliferation assay	10 μM	0, 24, 48, 72 h	DMSO	Both cell lines were sensitive to treatment with 10 μM 966. However, Hut78 cells exhibited a greater sensitivity than HH cells.	23894374
HH	Function assay	10 μM	24 h	DMSO	increases the acetylation at H3K9/K14, H3K27, and H4K5	23894374
Hut78	Function assay	10 μM	24 h	DMSO	increases the acetylation at H3K9/K14, H3K27, and H4K5	23894374
HL60	Antiproliferative assay		48 hrs		Antiproliferative activity against human HL60 cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay, IC50 = 1.64 μM.	29940115
K562	Antiproliferative assay		48 hrs		Antiproliferative activity against human K562 cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay, IC50 = 1.64 μM.	29940115
HEL	Antiproliferative assay		48 hrs		Antiproliferative activity against human HEL cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay, IC50 = 1.64 μM.	29940115
HL60	Antiproliferative assay		48 hrs		Antiproliferative activity against human HL60 cells after 48 hrs by CCK-8 assay, IC50 = 21.71 μM.	29940115
K562	Antiproliferative assay		48 hrs		Antiproliferative activity against human K562 cells after 48 hrs by CCK-8 assay, IC50 = 21.71 μM.	29940115
HEL	Antiproliferative assay		48 hrs		Antiproliferative activity against human HEL cells after 48 hrs by CCK-8 assay, IC50 = 21.71 μM.	29940115
Sf9	Function assay		60 mins		Inhibition of full length human C-terminal His-tagged HDAC3/N-terminal GST-tagged NCOR2 (395 to 489 residues) expressed in baculovirus infected Sf9 insect cells using substrate measured after 60 mins by colorimetric method	29541372
Click to View More Cell Line Experimental Data

Chemical Information, Storage & Stability

Molecular Weight	362.4	Formula	C₂₁H₁₉FN₄O	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1396841-57-8	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			Smiles	C1=CC=C(C=C1)C=CCN2C=C(C=N2)C=CC(=O)NC3=C(C=C(C=C3)F)N

Solubility

In vitro
Batch:

DMSO : 72 mg/mL (198.67 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	10%DMSO 1 40%PEG300 2 5%Tween80 3 45%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (13.80mM)	Taking the 1 mL working solution as an example, add 100 μL of 50 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 450 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.600mg/ml (9.93mM)	Taking the 1 mL working solution as an example, add 50 μL of 72 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 10%Tween80 3 45%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	3.600mg/ml (9.93mM)	Taking the 1 mL working solution as an example, add 50 μL of clarified DMSO stock solution of 72 mg/ml to 400 μL of PEG300, mix evenly to clarify it; add 100 μL of Tween80 to the above system, mix evenly to clarify it; then continue to add 450 μL of ddH2O to make it clear. Volume up to 1 mL. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	HDAC3 ^[1] (Cell-free assay) 80 nM
In vitro	RGFP966 is a slow-on/slow-off, competitive tight-binding HDAC inhibitor, with an IC50 of 0.08μM for HDAC3 and no effective inhibition of any other HDAC at concentrations up to 15μM. ^[1] This compound treatment on two CTCL cell lines for 24 hours prior to western blot analysis resulted in increased acetylation at H3K9/K14, H3K27, and H4K5, but not H3K56ac. It decreases cell growth in CTCL (cutaneous T cell lymphoma) cell lines due to increased apoptosis that is associated with DNA damage and impaired S phase progression. This chemical causes a significant reduction in DNA replication fork velocity within the first hour of drug treatment. ^[2]
Kinase Assay	Deacetylation assays
Kinase Assay	Deacetylation assays are based on the homogenous fluorescence release assay. Purified recombinant enzymes are incubated with serial-diluted inhibitors at the concentrations indicated in the figures, with pre-incubation times ranging from 0 to 3 hours, in the standard HDAC buffer. Acetyl-Lys(Ac)-AMC substrate (at 10 μM, corresponding to the Km for both HDAC1 and HDAC3) is added after the pre-incubation period. The reaction is allowed to run for 1 hour. The trypsin peptidase developer, at final concentration of 5mg/ml, is added after 1 hour, and the fluorescence emission is then measured using a Tecan M200 96-well plate reader.
In vivo	RGFP966 treatment (10 mg/kg) enhances long-term memory for object memory. This compound (3 or 10 mg/kg, s.c.) facilitates extinction and prevents reinstatement of cocaine- conditioned place preference. ^[1]
References	[1] https://pubmed.ncbi.nlm.nih.gov/23297220/ [2] https://pubmed.ncbi.nlm.nih.gov/23894374/

Applications

Methods	Biomarkers	Images	PMID
Western blot	p-STAT3 / Acetyl-STAT3 / STAT3 / Ac-H3 / Ac-H4 H3K9K14ac / H3 / H3K56ac / H3K27ac / H4K5ac		28338101

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Does this product S7229 specifically inhibit HDAC3? Or does it target other HDACs as well?

Answer:
In the paper, it is indicated that "this compound is specific for HDAC3, with an IC50 of 0.08 μM and no effective inhibition of any other HDAC at concentrations up to 15 μM." However, we did not perform experiment to confirm this data. Please refer to the following link for detailed information: http://www.pnas.org/content/110/7/2647.long

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):